Dr. Lubin Juarez Jr., MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 125 Medical Campus Dr Ste 300, Lansdale, PA 19446 Phone: 215-362-7125 Fax: 215-362-7175 |
News Archive
ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Zelegent, Inc. jointly announced today that the two companies have entered into an exclusive worldwide agreement to bring Zelegent's office-based Elevoplasty technology to board certified sleep specialists.
Researchers have finally found the genetic targets that could be used for treatment and development of new drugs in patients who are resistant to chemotherapy. These patients who are resistant to chemotherapy are most likely to have triple negative breast cancer which is the most aggressive form of breast cancer. The study appeared in the latest issue of the journal Cell Metabolism.
Democratic lawmakers and U.S. trade officials are in the final stages of negotiation over language to be added to international free trade agreements that would allow developing countries more flexibility in circumventing drug patents and other restrictions on pharmaceuticals, sources said recently, CongressDaily reports.
ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.
Americans age 50 and older who report that they have been incarcerated at some point in their lives are more likely to express anxiety about several aspects of retirement, to have experienced unemployment in the recent past, and to have fewer sources of income for retirement than those who have not, according to a new national survey of Americans age 50 and older from The Associated Press-NORC Center for Public Affairs Research.
› Verified 4 days ago